The University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, NC, USA.
Cancer Biol Ther. 2011 May 15;11(10):853-65. doi: 10.4161/cbt.11.10.15177.
Hundreds of hypermethylated genes have been described in breast cancer, yet the nature and contribution of these genes in their methylated state to overall risk and prognosis is under-characterized in non-sporadic breast cancers. We therefore compared associations of DNA methylation with tumor stage, hormone/growth receptor status, and clinical outcomes in a familial breast cancer cohort. Because few previous methylation studies have considered the oncogenic or tumor suppressor properties of their gene sets, this functional status was included as part of our correlative analysis.
We found methylation of oncogenes was associated with better prognostic indicators, whereas tumor suppressor gene methylation was associated with a more severe phenotype in women that were either HER2+ or lymph node positive at diagnosis, and/or tended to recur or develop distant metastases. For example, the methylation of the tumor suppressor gene APC was strongly associated with a specific subset of tumors that were both ER+ and HER2+, while methylation of the TWIST oncogene was associated with breast cancers that did not metastasize.
This was a retrospective, hospital-based study of n = 99 archival breast tumors derived from women with a germline genetic BRCA1 or BRCA2 mutation and/or familial breast cancer history. DNA methylation was quantified from formalin fixed, paraffin embedded tumors using the established protocol of quantitative multiplex-methylation specific PCR (QM-MSP). Non-parametric statistics were used to analyze candidate gene methylation in association with clinical outcomes.
We report several novel, positive associations between percent methylation of the APC, RASSF1A, TWIST, ERα, CDH1, and Cyclin D2 genes and key variables such as tumor stage, hormone and growth receptor status, and a history of recurrent or metastatic disease. Our data suggest the potential utility of parsing gene methylation by functional status and breast tumor subtype.
在乳腺癌中已经描述了数百个高甲基化基因,但这些基因在其甲基化状态下对非散发性乳腺癌的整体风险和预后的性质和贡献尚未得到充分描述。因此,我们在家族性乳腺癌队列中比较了 DNA 甲基化与肿瘤分期、激素/生长受体状态和临床结局的关联。由于以前的甲基化研究很少考虑其基因集的致癌或肿瘤抑制特性,因此该功能状态被包括在我们的相关分析中。
我们发现癌基因的甲基化与更好的预后指标相关,而肿瘤抑制基因的甲基化与 HER2+或诊断时淋巴结阳性的女性更严重的表型相关,并且/或者倾向于复发或发生远处转移。例如,肿瘤抑制基因 APC 的甲基化与既是 ER+又是 HER2+的特定肿瘤亚群密切相关,而 TWIST 癌基因的甲基化与不转移的乳腺癌相关。
这是一项回顾性的、基于医院的研究,共纳入了 99 例来自携带种系 BRCA1 或 BRCA2 突变和/或家族性乳腺癌病史的女性的存档乳腺癌肿瘤。使用定量多重甲基化特异性 PCR(QM-MSP)的既定方案,从福尔马林固定、石蜡包埋的肿瘤中定量 DNA 甲基化。非参数统计用于分析候选基因甲基化与临床结局的关联。
我们报告了 APC、RASSF1A、TWIST、ERα、CDH1 和 Cyclin D2 基因的甲基化百分比与肿瘤分期、激素和生长受体状态以及复发性或转移性疾病史等关键变量之间的几个新的正相关。我们的数据表明,通过功能状态和乳腺癌肿瘤亚型对基因甲基化进行细分的潜在效用。